Monitoring Tumor Heterogeneity and Detecting Resistance

EP: 1.Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy

EP: 2.Biological Mechanisms of GIST Resistance and Tumor Heterogeneity

Now Viewing

EP: 3.Monitoring Tumor Heterogeneity and Detecting Resistance

EP: 4.Post-Imatinib Progression: Decision Factors and Treatment Options

EP: 5.INVICTUS Trial: Ripretinib in Fourth-Line Setting

EP: 6.INTRIGUE Trial: Key Findings in Second-Line Setting

EP: 7.ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

EP: 8.Managing Adverse Events With Different TKIs

EP: 9.Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

EP: 10.Practical Recommendations for Community Oncologists

Video content above is prompted by the following:

• What tools do we currently have to monitor tumor heterogeneity and detect resistance? How reliable are our current testing methods in capturing the complete resistance profile?
• How does molecular testing differ for newly diagnosed metastatic patients vs those who have progressed on prior therapies?
• What role does liquid biopsy play compared to traditional tissue biopsy in detecting heterogeneity?
• How do you incorporate these test results into your risk assessment and clinical decision-making?